Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities

Oncologist

Volumn 6, Issue 1, 2001, Pages 34-55

  Jonasch, Eric ^a,b   Haluska, Frank G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Medicine   (United States)

Author keywords

Cancer; Clinical applications; Interferon; Management; Toxicity

Indexed keywords

ALPHA INTERFERON; ALPHAN3 INTERFERON; BETA1A INTERFERON; CONSENSUS INTERFERON; INTERFERON; INTERFERON BETA SERINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DEPRESSION; DRUG EFFECT; ENDOCRINE DISEASE; FATIGUE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; MOLECULAR CLONING; PRIORITY JOURNAL; SOMNOLENCE; THYROID DISEASE; TREATMENT INDICATION; VERTIGO;

BONE MARROW TRANSPLANTATION; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; LEUKEMIA, HAIRY CELL; LEUKEMIA, MYELOID, CHRONIC; LYMPHOMA, FOLLICULAR; MEDICAL ONCOLOGY; MELANOMA; QUALITY OF LIFE; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 0035134688     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-1-34     Document Type: Article

References (161)

1. Virus interference I. The interferon
2. The human interferon-alpha species and hybrid proteins
3. Interferon nomenclature
4. Signal transduction in the interferon system
5. Various human interferon alpha subclasses cross-react with common receptors: Their binding affinities correlate with their specific biological activities
6. 125I-labelled human interferons alpha, beta and gamma: Comparative receptor-binding data
7. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons
8. Biological therapy with interferon-alfa and beta: Preclinical studies
9. Safety profile of interferon-alpha therapy
10. Site-specific mutagenesis of the human fibroblast interferon gene
11. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta
12. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG)
13. Clinical pharmacokinetics of interferons
14. Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-beta serine
15. Phase I study of recombinant beta set 17 interferon in the treatment of cancer
16. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma
17. Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies
18. Expression cloning of 25A-dependent RNAase: A uniquely regulated mediator of interferon action
19. Anticellular and antiviral effects of pppA(2′p5′A)n
20. Constitutive expression of a 2′,5′-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression
21. Growth regulation of melanoma cells by interferon and (2′-5′)oligoadenylate synthetase
22. Modulation of 2′,5′-oligoadenylate synthetase in patients treated with alpha-interferon: Effects of dose, schedule, and route of administration
23. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants
24. A biological approach to optimize interferon treatment in hairy cell leukemia
25. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia
26. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: Preliminary results
27. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy
28. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients
29. MxA gene expression after live virus vaccination: A sensitive marker for endogenous type I interferon
30. Interferon-regulated Mx genes are not responsive to interleukin-1, tumor necrosis factor, and other cytokines
31. The human intracellular Mx-homologous protein is specifically induced by type I interferons
32. Alpha interferon for induction of remission in hairy-cell leukemia
33. Treatment of hairy cell leukemia with recombinant alpha-interferon
34. Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients
35. Human leukocyte interferon preparation blocks granulopoietic differentiation
36. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
37. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia
38. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
39. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583
40. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia
41. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group
42. UK Medical Research Council randomised, multicentre trial of interferon - Alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia
43. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
44. Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an open French multicentre randomized study
45. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML study group
46. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia
47. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine
48. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine
49. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
50. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French chronic myeloid leukemia study group
51. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma
52. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia
53. Treatment of chronic myelogenous leukemia with different cytokines
54. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia
55. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia
56. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia
57. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase
58. Recombinant interferon-alpha therapy in patients with follicular lymphoma
59. Interferon-alpha 2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress
60. The role of interferon in follicular lymphoma
61. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: An intergroup phase III trial (CALGB 8691 and EST 7486)
62. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
63. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the groupe d'Etude des lymphomes folliculaires 86 trial
64. CHOPBleo plus interferon for stage IV low-grade lymphoma
65. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: Prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only - A preliminary update of the German Low-grade Lymphoma Study Group
66. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-grade Lymphoma Study Group
67. Significant prolongation of disease-free survival in advanced low grade non-Hodgkin's lymphomas (NHL) by interferon alfa maintenance
68. Interferon-alfa-2a vs control as maintenance therapy for low grade non-Hodgkin's lymphoma: Results from a prospective randomized clinical trial
69. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival
70. Renal cell cancer
71. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators
72. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
73. Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2
74. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie
75. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial
76. Survival in renal cell carcinoma - A randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen
77. A randomized phase II trial of interleukin 2 and interleukin 2- interferon alpha in advanced renal cancer
78. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma
79. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma
80. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells
81. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: Relationship to the expression of thymidine phosphorylase
82. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
83. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil
84. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer
85. 5FU + subcutaneous (SC) interleukin-2 (IL2) plus SC Intron (IFN) in metastatic renal cell cancer (RCC) patients (pts). A CWG study
86. Interleukin-2 (IL-2) with interferon-α (IFN-α) and 5-fluorouracil (5-FU) in patients (pts) with metastatic renal cell carcer (RCC)
87. Fluoropyrimidines plus interleukin-2 and inteferon-α in the treatment of metastatic renal cell carcinoma: The UCLA kidney cancer program
88. Phase I/II trial of simultaneously administered rIL-2/rHuIFNα2a and 5-FU in patients (pts) with metastatic renal cell carcinoma (RCC)
89. Phase II trial of 5-fluorouracil interferon-alpha continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
90. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study. Subcutaneous administration propeukin program cooperative group
91. Randomized study of interleukin-2 (IL2) and interferon (IFN) with or without 5-FU (FUCY study) in metastatic renal cell carcinoma (MRCC)
92. Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients
93. Inhibition of growth of B16 murine malignant melanoma by exogenous interferon
94. Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society phase II trial
95. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma
96. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma
97. Interferon therapy: Melanoma
98. Interferons in melanoma
99. Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
100. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
101. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group Study
102. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma
103. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial
104. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha
105. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
106. Systemic chemotherapy and biotherapy
107. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
108. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma
109. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
110. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus Interleukin-2 (IL2) and Interferon-alpha-2b (INF) versus CVD in patients (Pts) with metastatic melanoma
111. Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b
112. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
113. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
114. Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high-and low-dose IFNa2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma
115. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: Clinical and immunological relevance
116. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
117. Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon
118. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma
119. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma
120. Approaches to interferon combination therapy in the treatment of AIDS
121. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma
122. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma
123. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: A phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS
124. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network study
125. Use of IFN-gamma in patients with AIDS
126. Treatment of Kaposi's sarcoma. Current guidelines and future perspectives
127. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma
128. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma
129. A perspective on the clinical effectiveness and tolerance of interferon-alpha
130. Fatigue: Definitions, mechanisms, and paradigms for study
131. Fatigue in patients with cancer receiving interferon alpha
132. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
133. Mood and cognitive side effects of interferon alfa therapy
134. Neurotoxicity of interferon alfa in melanoma therapy: Results from a randomized controlled trial
135. Interferon induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities
136. Mania induced by withdrawal of treatment with interferon alfa
137. Manic episode in two patients treated with inteferon alfa
138. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes
139. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha
140. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials
141. Effects of cytokines on the pituitary-adrenal axis in cancer patients
142. A study of anterior pituitary hormones secretion in patients with glioma receiving interferon-beta treatment
143. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro
144. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon
145. Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results
146. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma
147. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy
148. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha
149. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia
150. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis
151. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies
152. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer
153. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
154. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making
155. Patient utilities for adjuvant Interferon (IFN) treatment for high-risk melanoma
156. Cytoreduction nephrectomy in metastatic renal cancer: The results of Southwest Oncology Group Trial 8949
157. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma
158. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
159. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma
160. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study
161. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma [in Process Citation]